Therapeutic compounds and related methods of use

A compound of Formula I:

• wherein,
• R1 is —OR10, —CH2OR10, —CH2NR11R12, —C(O)R10, —C(O)OR10, —C(O)NR11R12, —OC(O)R10, —OC(O)OR10, —NR11R12, —OC(O)NR11R12, oxo, C1-C8 alkyl, C1-C8 heteroalkyl, halo, haloalkyl, cyclyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, or cyano;
• R1, together with R3, R5, or R6, and the atoms to which they are attached, may optionally form a heterocyclyl ring;
• R2 is —OR10, —SR10, —OC(O)R10, —OS(O)R10, —OC(O)OR10, —OS(O)OR10, cyano, —N3, —NR11R12, —NNR11, —OC(O)NR11R12, —SC(O)NR11R12, —P(R15R16)OR10, —OP(R15R16)OR10, —SP(R15R16)OR10, or —NHP(R15R16)OR10;
• L-M-T together form a structure selected from —C(R3)n—C(R3)n—C(R3)n—, —CR3═CR3—C(R3)n—, and —C(R3)n—CR3═CR3—;
• or L-M, M-T, or L-M-T, and one to three additional —C(R3)n—, —O—, —NR11—, or —S— to which they are bound, together form a 3-6 membered cyclyl, heterocyclyl, aryl, or heteroaryl ring, wherein n is independently 1 or 2;
• each R3 is independently H, halo, oxo, —OR10, —SR10, —OC(O)R10, —OS(O)R10, —OC(O)OR10, —OS(O)OR10, —OS(O)2R10, cyano, —N3, —NR11R12, —NNR11, —OC(O)NR11R12, —NR11C(O)OR12, —NR11′C(O)NR11R12, —SC(O)NR11R12, —NR11′S(O2)NR11R12, —P(R15R16)OR10, —OP(R15R16)OR10, —SP(R15R16)OR10, —NHP(R15R16)OR10, C1-C8 alkyl, C1-C8 heteroalkyl, cyclyl, heterocyclyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl;
• R5 is H, halo, oxo, —OR10, —SR10, —OC(O)R10, —OS(O)R10, —OC(O)OR10, —OS(O)OR10, cyano, —N3, —NR11R12, —NNR11, —OC(O)NR11R12, —NR11C(O)OR12, —NR11′C(O)NR11R12, —SC(O)NR11R12, —NR11′S(O2)NR11R12, —P(R15R16)OR10, —OP(R15R16)OR10, —SP(R15R16)OR10, or —NHP(R15R16)OR10;
• R6 is independently H, oxo, —OR10, —SR10, —COR10, —CNR11R12, —C(O)R10, —C(O)OR10, —C(O)NR11R12, —OC(O)R10, —OS(O)R10, —OC(O)OR10, —OS(O)OR10, —NR11R12, ═NR11, —OC(O)NR11R12, —SC(O)NR11R12, halo (e.g., F, Cl, Br, I), —NH2, cyano, C1-C8 alkyl, cyclylalkyl, or aryl;
• R5 and R6 together may optionally form a substituted or unsubstituted 5-8 membered cyclyl, heterocyclyl, aryl, or heteroaryl ring;
• R7 is H, halo, C1-C8 alkyl, or C1-C8 heteroalkyl;
• R10 is H, substituted or unsubstituted C1-C8 alkyl, C2-C8 alkenyl, C1-C8 heteroalkyl, substituted or unsubstituted C3-C8 cyclyl, C3-C8 heterocyclyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, or an amino acid side chain;
• R11, R11′, and R12 are each independently H, substituted or unsubstituted C1-C8 alkyl, C1-C8 heteroalkyl, C3-C8 cyclyl, C3-C8 heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, —OR13, —C(O)OR13, —OC(O)R13, —C(O)R13, —S(O)R13, —S(O2)R13, —NR131R14, cyano, or an amino acid side chain;
• R13 and R14 are each independently H, C1-C8 alkyl, C1-C8 heteroalkyl, —C(O)R10, C3-C8 cyclyl, C3-C8 heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, or cyano;
• R15 and R16 are each independently ═O, —S, —OR17, —SRN, or —NR17R18, provided R15 and R16 are not both double-bonded moieties;
• R17 and R18 are each independently H, C1-C8 alkyl, C1-C8 heteroalkyl, C3-C8 cyclyl, C3-C8 heterocyclyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl;
• R19 is —O—, —S—, —NR17—, —N(OH)—, or —N(OR10)—;
• and
• q is 1 or 2;
• provided that when R1 is —C(O)OH, n is 2, q is 1, R6 is oxo, and R7 is methyl, R2, R3, and R5 are not all hydroxy;
• provided that when R1 is —C(O)OH, R6 is oxo, R7 is methyl, and R3 and R5 are hydroxy, R2 is not benzoxy or benzyloxy;
• and provided that when R1 is —C(O)OH, R6 is oxo, R7 is methyl, and R2 is hydroxyl, R3 or R5 are not —OCH2Cl, —OCH2Br, or —OC(O)CH2Cl.